Evidence map›Paper›PMID 29027648›Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2017

Prevention of Type 2 Diabetes with the Chinese Herbal Medicine Tianqi Capsule: A Systematic Review and Meta-Analysis.

Bing Pang, Ying Zhang, Jing Liu, Li-Sha He, Yu-Jiao Zheng, Feng-Mei Lian, Xiao-Lin Tong

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this map
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bing PangDepartment of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Ying ZhangCentre for Evidence-Based Chinese Medicine, Beijing University of Traditional Chinese Medicine, Beijing, China.
Jing LiuSinobioway Group Co., Ltd., Heilongjiang Tian Ren Pharmaceutical Co., Ltd., Beijing, China.
Li-Sha HeDepartment of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Yu-Jiao ZhengDepartment of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Feng-Mei LianDepartment of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China. lfm565@sohu.com.
Xiao-Lin TongDepartment of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China. xiaolintong66@sina.com.
Guang’anmen Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

The Major Program of the National Natural Science Foundation of China 81430097
6 · The paper itself

Abstract

introductionPrevention of the rapid growth in incidence of type 2 diabetes (T2DM) is a big challenge for clinicians. In China, many trials have indicated that Tianqi capsule, which contains several Chinese herbal medicines as part of a large healing system called traditional Chinese medicine, could decrease the incidence of T2DM. The review assessed the effectiveness of Tianqi capsule in prevention of T2DM.

methodsSeven electronic databases were searched to identify eligible trials published from the inception of the databases up until May 1, 2017. Randomized controlled trials (RCTs) of Tianqi capsule for impaired glucose tolerance (IGT) were included. Data extraction and quality assessment were performed according to the Cochrane review standards. A random or a fixed effect model was used to analyze outcomes which were expressed as risk ratios (RRs) or mean differences (MD), and I

resultsSix trials were identified that included 1027 subjects. Meta-analysis showed that subjects who received Tianqi capsule plus lifestyle modification (LM) were less likely to progress to T2DM compared to controls (RR 0.55, 95% CI 0.44-0.68). Subjects who received Tianqi capsule plus LM were more likely to have glucose return to normal compared to controls (RR 0.69; 95% CI 0.62-0.78); and they had reduced fasting plasma glucose (FBG) (MD - 0.35; 95% CI - 0.55 to - 0.16) and 2-h plasma glucose (2 h PG) (MD - 1.04; 95% CI - 1.75 to - 0.32). There was no statistical difference between the two groups for IGT stabilized incidence (RR 0.89; 95% CI 0.71-1.12). No obvious adverse events occurred.

conclusionIn patients with IGT, Tianqi capsule reduced the risk of progression to T2DM and increased the possibility of regression toward normoglycemia. As a result of the limited number of RCTs and the methodological drawbacks of the included studies, the results should be interpreted with caution.

Indexed as

Diabetes preventionImpaired glucose toleranceMeta-analysisRandomized controlled trialsTianqi capsule

Identifiers

PMID29027648
PMCPMC5688982
OpenAlexW2763546944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.